

## **Part VI: Summary of the risk management plan**

### **Summary of risk management plan for Roxithromycin Medical Valley (roxithromycin)**

This is a summary of the risk management plan (RMP) for Roxithromycin Medical Valley. The RMP details important risks of Roxithromycin Medical Valley, and how more information will be obtained about Roxithromycin Medical Valley's risks and uncertainties (missing information).

Roxithromycin Medical Valley's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Roxithromycin Medical Valley should be used.

Important new concerns or changes to the current ones will be included in updates of Roxithromycin Medical Valley's RMP.

#### **I. The medicine and what it is used for**

Roxithromycin Medical Valley is authorised for:

the treatment of infections due to roxithromycin susceptible microorganisms. Such infections include:

*Respiratory infections:* Community-acquired pneumonia, in particular pneumonia caused by *Mycoplasma pneumoniae*, *Chlamydia psittaci* (ornithosis) or *Chlamydia pneumoniae* (TW AR).

Tonsillitis, pharyngitis, acute otitis media in patients with hypersensitivity to beta lactam antibiotics, or when such treatment is considered unsuitable for other reasons.

*Urogenital infections* caused by *Chlamydia trachomatis* (namely urethritis or cervicitis).

*Skin and soft tissue infections:* such as furunculosis, pyoderma, impetigo, erysipelas in patients with hypersensitivity to beta lactam antibiotics, or when such treatment is considered unsuitable for other reasons.

It contains roxithromycin as the active substance, and it is given by the oral route.

#### **II. Risks associated with the medicine and activities to minimise or further characterise the risks**

Important risks of Roxithromycin Medical Valley, together with measures to minimise such risks and the proposed studies for learning more about Roxithromycin Medical Valley's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;

- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

## ***II.A List of important risks and missing information***

Important risks of Roxithromycin Medical Valley are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Roxithromycin Medical Valley. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

<b>List of important risks and missing information</b>	
Important identified risks	None
Important potential risks	None
Missing information	None

## ***II.B Summary of important risks***

The safety information in the Product Information is aligned to the reference medicinal product.

## ***II.C Post-authorisation development plan***

### **II.C.1 Studies which are conditions of the marketing authorisation**

There are no studies which are conditions of the marketing authorisation or specific obligation of Roxithromycin Medical Valley.

### **II.C.2 Other studies in post-authorisation development plan**

There are no studies required for Roxithromycin Medical Valley.